Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
ACRV

Acrivon Therapeutics, Inc. Common Stock

ACRV

NASDAQ·Healthcare·Biotechnology·Mkt cap $91.2M

$2.13

▲ +3.40%

P/E

-1.13

Mkt Cap

$91.2M

52-Wk Range

$1.27–$3.56

52-Week Range

$1.27 - $3.56

P/E

-1.13

Fwd P/E

-1.12

Beta

1.93

Div Yield

0.00%

Avg Vol

415.5K

Shares Out

31.6M

Mkt Cap

$91.2M

Price action

Price chart

Up 19.0% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary Acrivon Predictive Precision Proteomics platform enabling drug-specific patient stratification
  • Integrated companion diagnostic development reducing clinical trial risk and improving efficacy outcomes
  • Focused pipeline targeting validated pathways in DNA damage response and cell cycle regulation
  • First-mover advantage in precision proteomics-based patient responder identification for oncology
▼

Bear Case

1 risk

  • Above-average volatility (beta 1.9).

Growth

Stable outlook

Advancement of ACR-368 through potentially registrational Phase 2 trials across multiple tumor types

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+49.0% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 12, 2026

“
Q3 26 RECAP

AUG 12, 2026

Reported EPS of -$0.43 vs -$0.50 consensus (+14.4% surprise).

EPS beat +14.4%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+14.4%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

View full analyst page →

vs Industry

How ACRV stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.